PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Get Free Report) has earned a consensus recommendation of "Buy" from the six research firms that are covering the stock, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $5.80.
PMVP has been the topic of a number of recent research reports. Oppenheimer upgraded shares of PMV Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $6.00 price target on the stock in a research note on Friday. HC Wainwright restated a "buy" rating and issued a $5.00 target price on shares of PMV Pharmaceuticals in a research note on Tuesday, August 20th.
Get Our Latest Analysis on PMVP
PMV Pharmaceuticals Stock Down 1.1 %
Shares of PMVP traded down $0.02 during mid-day trading on Friday, hitting $1.76. 277,732 shares of the company's stock were exchanged, compared to its average volume of 411,013. The stock's 50-day simple moving average is $1.55 and its 200-day simple moving average is $1.66. PMV Pharmaceuticals has a 52 week low of $1.40 and a 52 week high of $3.47.
PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.32. Equities research analysts forecast that PMV Pharmaceuticals will post -1.05 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. acquired a new position in PMV Pharmaceuticals in the 1st quarter worth about $26,000. Public Employees Retirement System of Ohio raised its holdings in PMV Pharmaceuticals by 174.2% in the first quarter. Public Employees Retirement System of Ohio now owns 22,757 shares of the company's stock valued at $39,000 after acquiring an additional 14,457 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in PMV Pharmaceuticals by 71.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 42,802 shares of the company's stock valued at $73,000 after purchasing an additional 17,858 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of PMV Pharmaceuticals in the second quarter valued at approximately $101,000. Finally, Evoke Wealth LLC acquired a new position in shares of PMV Pharmaceuticals in the second quarter worth $102,000. Institutional investors and hedge funds own 90.20% of the company's stock.
PMV Pharmaceuticals Company Profile
(
Get Free ReportPMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.
Further Reading
Before you consider PMV Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PMV Pharmaceuticals wasn't on the list.
While PMV Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
